Deep Dive Moving from autologous to allogeneic ACT paradigms We have come so far in a relatively short time with Adoptive Cellular Transfer (ACT).
Deep Dive Did cancer clinical trials stay on track at ASCO 2019? Chicago is recovering after 40,000 oncologists and cancer experts descended on the city for this year’s ASCO conference.
Deep Dive Why pharma needs honest patient dialogue Astellas Pharma US president Percival Barretto-Ko talks with Dr Paul Tunnah about drug pricing, collaboration and improving the patient experience.
Oncology Deep Dive: Oncology and ASCO 2019 Oncology is currently a more cutting-edge, dynamic field than it has ever been – as demonstrated at this year’s American Society of Clinical Oncology (ASCO) conference.
News ESMO26: Sac-TMT delivers the goods in PD-L1-negative NSCLC Kelun and MSD's TROP2-directed ADC, sac-TMT, reduced the risk of disease progression or death by 51% when used first-line in PD-L1-negative NSCLC.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
